• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PGC-1alpha 基因的编码可改变亨廷顿病的发病年龄。

The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease.

机构信息

Department of Neurology, University of Ulm (P,W,; G,B,L,), Ulm, Germany.

出版信息

Mol Neurodegener. 2009 Jan 8;4:3. doi: 10.1186/1750-1326-4-3.

DOI:10.1186/1750-1326-4-3
PMID:19133136
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2630305/
Abstract

Huntington's disease (HD) is one of the most common autosomal dominant inherited, neurodegenerative disorders. It is characterized by progressive motor, emotional and cognitive dysfunction. In addition metabolic abnormalities such as wasting and altered energy expenditure are increasingly recognized as clinical hallmarks of the disease. HD is caused by an unstable CAG repeat expansion in the HD gene (HTT), localized on chromosome 4p16.3. The number of CAG repeats in the HD gene is the main predictor of disease-onset, but the remaining variation is strongly heritable. Transcriptional dysregulation, mitochondrial dysfunction and enhanced oxidative stress have been implicated in the pathogenesis. Recent studies suggest that PGC-1alpha, a transcriptional master regulator of mitochondrial biogenesis and metabolism, is defective in HD. A genome wide search for modifier genes of HD age-of-onset had suggested linkage at chromosomal region 4p16-4p15, near the locus of PPARGC1A, the gene coding for PGC-1alpha. We now present data of 2-loci PPARGC1A block 2 haplotypes, showing an effect upon age-at-onset in 447 unrelated HD patients after statistical consideration of CAG repeat lengths in both HTT alleles. Block 1 haplotypes were not associated with the age-at-onset. Homozygosity for the 'protective' block 2 haplotype was associated with a significant delay in disease onset. To our knowledge this is the first study to show clinically relevant effects of the PGC-1alpha system on the course of Huntington's disease in humans.

摘要

亨廷顿病(HD)是最常见的常染色体显性遗传、神经退行性疾病之一。其特征是进行性运动、情感和认知功能障碍。此外,代谢异常,如消瘦和能量消耗改变,也越来越被认为是该疾病的临床特征。HD 是由 HTT 基因(位于 4p16.3 染色体上)中不稳定的 CAG 重复扩展引起的。HD 基因中 CAG 重复的数量是疾病发作的主要预测因素,但其余的变异是强烈可遗传的。转录失调、线粒体功能障碍和增强的氧化应激已被牵涉到发病机制中。最近的研究表明,PGC-1alpha 是线粒体生物发生和代谢的转录主调控因子,在 HD 中存在缺陷。对 HD 发病年龄的修饰基因的全基因组搜索表明,在编码 PGC-1alpha 的基因 PPARGC1A 附近的 4p16-4p15 染色体区域存在连锁。我们现在提供了 2 个 PPARGC1A 块 2 单倍型的多态性数据,在考虑了 HTT 等位基因中 CAG 重复长度后,在 447 名无关的 HD 患者中,该数据显示对发病年龄有影响。块 1 单倍型与发病年龄无关。保护性块 2 单倍型的纯合性与疾病发作的显著延迟有关。据我们所知,这是第一项在人类亨廷顿病中显示 PGC-1alpha 系统对疾病进程具有临床相关影响的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d4a/2630305/a35e03b713fd/1750-1326-4-3-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d4a/2630305/a35e03b713fd/1750-1326-4-3-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d4a/2630305/a35e03b713fd/1750-1326-4-3-1.jpg

相似文献

1
The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease.PGC-1alpha 基因的编码可改变亨廷顿病的发病年龄。
Mol Neurodegener. 2009 Jan 8;4:3. doi: 10.1186/1750-1326-4-3.
2
A modifier of Huntington's disease onset at the MLH1 locus.MLH1基因座处亨廷顿病发病的一个修饰因子。
Hum Mol Genet. 2017 Oct 1;26(19):3859-3867. doi: 10.1093/hmg/ddx286.
3
[Molecular genetics of Huntington's disease].[亨廷顿舞蹈症的分子遗传学]
Rinsho Shinkeigaku. 1995 Dec;35(12):1529-31.
4
Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.亨廷顿舞蹈病转基因小鼠的体温调节和代谢缺陷表明,PGC-1α与亨廷顿舞蹈病神经变性有关。
Cell Metab. 2006 Nov;4(5):349-62. doi: 10.1016/j.cmet.2006.10.004. Epub 2006 Oct 19.
5
PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function.PGC-1α 通过防止氧化应激和促进 TFEB 功能来挽救亨廷顿病的蛋白毒性。
Sci Transl Med. 2012 Jul 11;4(142):142ra97. doi: 10.1126/scitranslmed.3003799.
6
Investigation of the Influence of TBP CAG/CAA Repeats in Conjunction with HTT CAG Repeats on Huntington's Disease Age at Onset in a Brazilian Sample.探讨 TBP CAG/CAA 重复与 HTT CAG 重复联合对巴西人群亨廷顿病发病年龄的影响。
J Mol Neurosci. 2022 May;72(5):1116-1124. doi: 10.1007/s12031-021-01938-z. Epub 2022 Mar 11.
7
PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease.PGC-1alpha 下游转录因子 NRF-1 和 TFAM 是亨廷顿病的遗传修饰因子。
Mol Neurodegener. 2011 May 19;6(1):32. doi: 10.1186/1750-1326-6-32.
8
Multiple clinical features of Huntington's disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration.亨廷顿病的多种临床特征与突变 HTT 基因 CAG 重复长度和神经退行性变相关。
J Neurol. 2019 Mar;266(3):551-564. doi: 10.1007/s00415-018-8940-6. Epub 2018 Jun 28.
9
The role of PGC-1α in the pathogenesis of neurodegenerative disorders.PGC-1α 在神经退行性疾病发病机制中的作用。
Curr Drug Targets. 2010 Oct;11(10):1262-9. doi: 10.2174/1389450111007011262.
10
Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.烟酰胺可改善亨廷顿病模型小鼠的运动缺陷,并上调 PGC-1α 和 BDNF 基因的表达。
Neurobiol Dis. 2011 Jan;41(1):43-50. doi: 10.1016/j.nbd.2010.08.017. Epub 2010 Aug 22.

引用本文的文献

1
Oxidative Stress in Huntington's Disease.亨廷顿舞蹈症中的氧化应激
Biomolecules. 2025 Apr 4;15(4):527. doi: 10.3390/biom15040527.
2
Study insights in the role of PGC-1α in neurological diseases: mechanisms and therapeutic potential.PGC-1α在神经系统疾病中的作用研究见解:机制与治疗潜力
Front Aging Neurosci. 2025 Feb 12;16:1454735. doi: 10.3389/fnagi.2024.1454735. eCollection 2024.
3
Modification of Huntington's disease by short tandem repeats.短串联重复序列对亨廷顿舞蹈症的修饰作用

本文引用的文献

1
The current clinical management of Huntington's disease.亨廷顿舞蹈症的当前临床管理
Mov Disord. 2008 Aug 15;23(11):1491-504. doi: 10.1002/mds.21971.
2
Huntingtin-associated protein-1 is a modifier of the age-at-onset of Huntington's disease.亨廷顿蛋白相关蛋白-1是亨廷顿舞蹈病发病年龄的一个修饰因子。
Hum Mol Genet. 2008 Apr 15;17(8):1137-46. doi: 10.1093/hmg/ddn003. Epub 2008 Jan 11.
3
Huntington's disease phenocopy syndromes.亨廷顿病表型模拟综合征
Brain Commun. 2024 Jan 23;6(2):fcae016. doi: 10.1093/braincomms/fcae016. eCollection 2024.
4
Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases.过氧化物酶体增殖物激活受体γ共激活因子-1(PGC-1)家族在生理和病理生理过程及疾病中的作用。
Signal Transduct Target Ther. 2024 Mar 1;9(1):50. doi: 10.1038/s41392-024-01756-w.
5
The translational potential of cholesterol-based therapies for neurological disease.胆固醇类疗法治疗神经疾病的转化潜力。
Nat Rev Neurol. 2023 Oct;19(10):583-598. doi: 10.1038/s41582-023-00864-5. Epub 2023 Aug 29.
6
From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington's Disease Research.从发病机制到治疗:亨廷顿病研究 150 年回顾。
Int J Mol Sci. 2023 Aug 21;24(16):13021. doi: 10.3390/ijms241613021.
7
Interactive Associations between and and Bisphosphonate-Related Osteonecrosis of the Jaw in Patients with Osteoporosis.骨质疏松症患者中[具体内容缺失]与[具体内容缺失]及双膦酸盐相关颌骨坏死之间的交互关联。
Pharmaceuticals (Basel). 2023 Jul 21;16(7):1035. doi: 10.3390/ph16071035.
8
Integrated Bioinformatics Analysis of Shared Genes, miRNA, Biological Pathways and Their Potential Role as Therapeutic Targets in Huntington's Disease Stages.共享基因、miRNA、生物途径的综合生物信息学分析及其在亨廷顿病各阶段作为治疗靶点的潜在作用。
Int J Mol Sci. 2023 Mar 2;24(5):4873. doi: 10.3390/ijms24054873.
9
Emerging Role of NLRP3 Inflammasome/Pyroptosis in Huntington's Disease.NLRP3 炎性小体/细胞焦亡在亨廷顿病中的新兴作用。
Int J Mol Sci. 2022 Jul 28;23(15):8363. doi: 10.3390/ijms23158363.
10
Deciphering the role of PGC-1α in neurological disorders: from mitochondrial dysfunction to synaptic failure.解读PGC-1α在神经疾病中的作用:从线粒体功能障碍到突触功能衰竭
Neural Regen Res. 2022 Feb;17(2):237-245. doi: 10.4103/1673-5374.317957.
Curr Opin Neurol. 2007 Dec;20(6):681-7. doi: 10.1097/WCO.0b013e3282f12074.
4
Targeting PGC-1 alpha to control energy homeostasis.靶向过氧化物酶体增殖物激活受体γ共激活因子1α以控制能量平衡。
Expert Opin Ther Targets. 2007 Oct;11(10):1329-38. doi: 10.1517/14728222.11.10.1329.
5
Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression.亨廷顿病的早期能量不足:在疾病进展过程中可追踪的血浆生物标志物的鉴定。
PLoS One. 2007 Jul 25;2(7):e647. doi: 10.1371/journal.pone.0000647.
6
Huntington's disease.亨廷顿舞蹈症
Lancet. 2007 Jan 20;369(9557):218-28. doi: 10.1016/S0140-6736(07)60111-1.
7
Multiple pathways contribute to the pathogenesis of Huntington disease.多种途径参与亨廷顿舞蹈症的发病机制。
Mol Neurodegener. 2006 Dec 16;1:19. doi: 10.1186/1750-1326-1-19.
8
PGC-1alpha, a new therapeutic target in Huntington's disease?PGC-1α,亨廷顿舞蹈症的一个新治疗靶点?
Cell. 2006 Nov 3;127(3):465-8. doi: 10.1016/j.cell.2006.10.023.
9
Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.亨廷顿舞蹈病转基因小鼠的体温调节和代谢缺陷表明,PGC-1α与亨廷顿舞蹈病神经变性有关。
Cell Metab. 2006 Nov;4(5):349-62. doi: 10.1016/j.cmet.2006.10.004. Epub 2006 Oct 19.
10
Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators.PGC-1转录共激活因子对活性氧的抑制作用及对神经退行性变的影响
Cell. 2006 Oct 20;127(2):397-408. doi: 10.1016/j.cell.2006.09.024.